Quantcast

Immunotech Laboratories and Its Novel HIV/AIDS Therapeutic Could Benefit From House Resolution to Support Small Biotechnology Companies

December 20, 2010

Immunotech Laboratories developer of a IPF, unique immune therapeutic treatment for HIV/AIDS announced that Congressman Danny K. Davis (Il-7th) submitted House Resolution 1179, a significant piece of legislation that puts Congress on record in supporting biotechnology firms that meet small business standards, their intellectual property, the importance of the impact of various innovative therapies to treat a variety of life threatening conditions, including pandemic diseases. Immunotech Laboratories, Inc. (IMMB), along with a group of other biotech companies, has taken an active role supporting the legislation and actively working for its eventual passage. The legislation encourages federal agencies to develop a coordinated, national approach to the small biotechnology sector to develop and coordinate resources and funding mechanisms to preserve and enhance the survival of these firms. The resolution can be found online at http://thomas.gov/cgi-bin/query/z?c111:H.RES.1179:

Glendale, CA (PRWEB) December 19, 2010

Immunotech Laboratories developer of a IPF, unique immune therapeutic treatment for HIV/AIDS announced that Congressman Danny K. Davis (Il-7th) submitted House Resolution 1179, a significant piece of legislation that puts Congress on record in supporting biotechnology firms that meet small business standards, their intellectual property, the importance of the impact of various innovative therapies to treat a variety of life threatening conditions, including pandemic diseases. Immunotech Laboratories, Inc. (IMMB), along with a group of other biotech companies, has taken an active role supporting the legislation and actively working for its eventual passage. The legislation encourages federal agencies to develop a coordinated, national approach to the small biotechnology sector to develop and coordinate resources and funding mechanisms to preserve and enhance the survival of these firms. The resolution can be found online at http://thomas.gov/cgi-bin/query/z?c111:H.RES.1179:

House Resolution 1179 states:

“Almost every state has a variety of biotechnology companies vital to the health and well-being of the people and economy of that state. This is a non-partisan issue and I ask my fellow Members, both Democrats and Republicans, to join me in this effort,” Rep. Davis said. “Biotechnology is an important contributor to the jobs and intellectual capital. It promotes healthcare innovation across the country and an ability to compete in a global marketplace.”

“Immunotech’s Irreversible Pepsin Fraction (IPF) displays significant antiviral activity without indications of resistance based on lab data,” said Harry Zhabilov, Chief Science Officer, Immunotech Laboratories during the 5th European Conference on Clinical and Social Research on AIDS and Drugs, Vilnius, Lithuania.

The legislation encourages therapies and new drug development to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases, including those in medically underserved communities. The key to the legislation is congressional support of point of care therapeutics and diagnostics by emerging and small biotechnology firms for domestic and global use.

“It is a great pleasure to note that within the several sciences noted in House Resolution 1179, Irreversible Pepsin Fraction is one that Immunotech Laboratories, Inc. has as its main platform technology and holds the patent for,” said Harry Zhabilov, Chief Science Officer of Immunotech.

About Immunotech Laboratories, Inc.

Immunotech Laboratories Inc. (IMMB) holds the licensing rights of the Irreversible Pepsin Fraction (IPF) peptide molecule for the specific treatment of the HIV/AIDS indication. IPF has demonstrated to have both fusion inhibitor and immunomodulator capabilities during the studies. Researchers hope this will provide opportunities for patients that have already shown resistance to one or more antiretroviral therapies.

Immunotech Laboratories develops novel therapeutic molecules for the treatment of HIV/AIDS. The Company maintains a research pipeline with potential treatments for pre-natal and pediatric HIV/AIDS patients, with intent to pursue a preventive HIV vaccine. The U.S. Patent office has granted full patent rights for IPF under patent number 7479538. Immunotech Laboratories intends to complete pre-clinical studies in order to obtain FDA clearance to initiate clinical phase I studies, which are projected to start the 4th quarter of 2010. The Company is seeking fast track status designation from the FDA.

Safe Harbor Statement

Except for historical information, the matters discussed in this news release may be considered “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of Immunotech Laboratories, Inc. and its management and are valid only as of today, and we disclaim any obligation to update this information. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a difference include, among others the successful pre-clinical development, the successful completion of clinical trials, the FDA review process and other governmental regulation, pharmaceutical collaborator interest and ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third party reimbursement, and other factors.

CONTACT: Ara Ghanime or Harry Zhabilov 818-409-9091

###

For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2010/12/prweb4910334.htm


Source: prweb



comments powered by Disqus